Abstract 1416P
Background
Infusion-related reaction (IRR) are a common toxicty of amivantamab, with a high incidence during the first infusion (97%). However, subsequent injections are usually not affected, unless there is a delay in treatment for several weeks. We evaluate the risk of IRR after the resumption of amivantamab, based on the duration of the free treatment interval.
Methods
This was a retrospective observational study to evaluate the recurrence of IRR in advanced non-small cell lung cancer patients treated with amivantamab and lazertinib in Gustave Roussy (2019-2023).
Results
Baseline characteristics of patients are summarized in the table. 24 patients were included, 12 (50%) presented IRR during the first infusion, and only one of them presented previous history of allergy. 9 patients had a temporary discontinuation of treatment, but only 2 had an IRR recurrence (these 2 had experienced an IRR during first cycle). Median time of treatment discontinuation was of 25.57 days for those patients without IRR recurrence and 44 days for those who presented it. Both patients with IRR recurrence had a temporary withdrawal due to another toxicity (at day 29 and 59 respectively) being of CTCAE grade 3 and 2 respectively. 5 patients (41.6%) needed corticoesteroids and 6 (50%) received antihistamines as treatment for the IRR. Only one patient required magnesium sulfate. A third IRR recurrence was experienced in both patients (grade 2 and 1 respectively), leading to permanent treatment discontinuation for one patient. None of the patients progressed to amivantamab and both are still alive. Table: 1416P
Gender (N) Female Male | 15 9 |
Median age, Years (IQR) | 66 (39-81) |
Molecular profile (N) EGFR exon 19 EGFR exon 20 EGFR L858R MET overexpression MET exon 14 skipping mutation | 11 1 9 1 2 |
Median number of previous lines (IQR) | 2 |
Conclusions
Recurrence of IRR after the first episode is frequent and must be taken into account when reintroducing amivantamab after a temporary withdrawal of ≥1 month. IRR recurrence does not seem to have a detrimental impact on treatment efficacy.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
J. Remon Masip: Financial Interests, Personal, Invited Speaker: Roche, MSD, Boehringer Ingelheim; Financial Interests, Personal, Writing Engagement: Pfizer; Financial Interests, Personal, Advisory Board: AstraZeneca, Ose Immunotherapeutics, BMS, Janssen, Takeda, Sanofi; Financial Interests, Institutional, Invited Speaker: Merck Portugal; Non-Financial Interests, Principal Investigator, PI of PECATI trial in Thymic malignancies endorsed by a grant by MSD: MSD; Non-Financial Interests, Other, Co-PI of APPLE trial (EORTC-1525): AstraZeneca; Non-Financial Interests, Member, Secretary of the Lung Cancer Group at the EORTC: EORTC. A. Gazzah: Non-Financial Interests, Advisory Board: AstraZeneca, Bayer, BMS, Boehringer Ingelheim, Johnson & Johnson, Lilly, Medimmune, Merck, NH TherAGuiX, Pfizer, Roche; Financial Interests, Advisory Board: Novartis, Sanofi , Roche, Pfizer, Novartis, Boehringer Ingelheim; Financial Interests, Principal Investigator: Amgen, Astex, Argen-X Byba, Bristol Myer Squibb, Celegne, Gilead, Lilly, Novartis, Pharma Mar, Pierre Fabre, Merck Sharp. P. Lavaud: Financial Interests, Advisory Board: Astellas, AstraZeneca, Janssen, Sanofi; Non-Financial Interests, Advisory Board: AstraZeneca, Hoffman-La Roche; Other: Astellas. A. Levy: Financial Interests, Institutional, Invited Speaker: Pharma Mar; Financial Interests, Institutional, Funding: AstraZeneca; Financial Interests, Institutional, Coordinating PI: BeiGene. S. Ponce Aix: Financial Interests, Advisory Board: BMS, MSD, Roche, AstraZeneca, Takeda. F. Barlesi: Financial Interests, Institutional, Advisory Board: AstraZeneca, Bayer, Bristol Myers Squibb, Boehringer Ingelheim, Eli Lilly Oncology, F. Hoffmann–La Roche Ltd, Novartis, Merck, Mirati, MSD, Pierre Fabre, Pfizer, Sanofi Aventis, Seattle Genetics, Takeda, AbbVie, Acea, Amgen, Eisai, Ignyta; Non-Financial Interests, Principal Investigator: AstraZeneca, BMS, Merck, Pierre Fabre, F. Hoffmann-La Roche Ltd., Innate Pharma, Mirati. D. Planchard: Financial Interests, Personal, Advisory Board: AstraZeneca, BMS, Merck, Novartis, Pfizer, Roche, Samsung, Celgene, AbbVie, Daiichi Sankyo, Janssen, Seagen, Gilead, Pierre Fabre; Financial Interests, Personal, Invited Speaker: AstraZeneca, Novartis, Pfizer, priME Oncology, Peer CME, Samsung, AbbVie, Janssen; Non-Financial Interests, Principal Investigator, Institutional financial interests: AstraZeneca, BMS, Merck, Novartis, Pfizer, Roche, Daiichi Sankyo, Sanofi-Aventis, Pierre Fabre; Non-Financial Interests, Principal Investigator: AbbVie, Sanofi, Janssen. B. Besse: Financial Interests, Institutional, Funding: 4D Pharma, AbbVie, Amgen, Aptitude Health, AstraZeneca, BeiGene, Blueprint Medicines, Boehringer Ingelheim, Celgene, Cergentis, Cristal Therapeutics, Daiichi Sankyo, Eli Lilly, GSK, Janssen, Onxeo, Ose Immunotherapeutics, Pfizer, Roche-Genentech, Sanofi, Takeda, Tolero Pharmaceuticals; Financial Interests, Institutional, Research Grant: Chugai Pharmaceutical, Eisai, Genzyme Corporation, Inivata, Ipsen, Turning Point Therapeutics. All other authors have declared no conflicts of interest.
Resources from the same session
1368P - LUMINATE 102: A real-world study on biomarker testing rates among patients with non-small cell lung cancer (NSCLC) across lines of therapy
Presenter: Charu Aggarwal
Session: Poster session 20
1369P - BrigAlec study: Focus on alectinib efficacy after brigatinib exposure in BrigALK2 study (GFPC 02-2019)
Presenter: Renaud Descourt
Session: Poster session 20
1370P - Efficacy and safety of ensartinib in ALK-positive non-small cell lung cancer patients with brain metastases: A multicenter, open-label, single-arm, phase II study
Presenter: Jianhua Chang
Session: Poster session 20
1371P - First-line alectinib vs. brigatinib in advanced metastatic NSCLC with ALK rearrangement: Real-world data
Presenter: Young Kyung Jeon
Session: Poster session 20
1372P - Repotrectinib in patients (pts) with NTRK fusion-positive (NTRK+) advanced solid tumors, including NSCLC: Update from the phase I/II TRIDENT-1 trial
Presenter: Ben Solomon
Session: Poster session 20
1373P - Efficacy and safety of taletrectinib in patients (Pts) with ROS1+ non-small cell lung cancer (NSCLC): Interim analysis of global TRUST-II study
Presenter: Maurice Pérol
Session: Poster session 20
1374P - Survival and therapy analysis of small-scale ROS1-mutant non-small cell lung cancer (NSCLC) patients
Presenter: Moritz Glaser
Session: Poster session 20
1375P - Beamion Lung 1, an ongoing phase Ia/Ib trial of the HER2 TKI, BI 1810631 in patients (pts) with advanced solid tumors with HER2 aberrations: Latest data
Presenter: Frans Opdam
Session: Poster session 20
1377P - Differential impact of EGFR exon 20 insertion location on tyrosine kinase inhibitor sensitivity
Presenter: Xiuning Le
Session: Poster session 20
1378P - Efficacy and safety of tunlametinib (HL-085) combined with vemurafenib in patients with advanced BRAF V600-mutated solid tumors: A multicenter, phase I study
Presenter: Yuan-Kai Shi
Session: Poster session 20